Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

143.72 -1.09 (-0.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

February 22, 2025

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

Via MarketBeat

Topics Death

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

February 20, 2025

From Gilead Sciences, Inc.

Via Business Wire

How Is The Market Feeling About Gilead Sciences? ↗

February 19, 2025

Via Benzinga

16 Analysts Have This To Say About Gilead Sciences ↗

February 18, 2025

Via Benzinga

Why Gilead Sciences Stock Is Jumping Today ↗

February 12, 2025

Via The Motley Fool

Gilead Sciences to Present at Upcoming Investor Conferences

February 19, 2025

From Gilead Sciences, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 18, 2025

Via Benzinga

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

February 18, 2025

From Gilead Sciences, Inc.

Via Business Wire

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

February 18, 2025

Via Benzinga

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Bullish Setups ↗

February 16, 2025

You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now.

Via Talk Markets

Topics Stocks / Equities

Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday ↗

February 13, 2025

Via Benzinga

Moderna (MRNA) Q4 Earnings Report Preview: What To Look For

February 13, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.

Via StockStory

Top S&P500 movers in Wednesday's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗

February 12, 2025

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Via Benzinga

These S&P500 stocks have an unusual volume in today's session ↗

February 12, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Via Chartmill

Why Gilead Sciences (GILD) Stock Is Trading Up Today

February 12, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS,...

Via StockStory

These S&P500 stocks are moving in today's session ↗

February 12, 2025

Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗

February 12, 2025

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New...

Via Benzinga

Topics Economy

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗

February 12, 2025

Via Benzinga

Discover the top S&P500 movers in Wednesday's pre-market session. ↗

February 12, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs ↗

February 12, 2025

Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline.

Via Stocktwits

Markets Mixed On Powell Testimony, Q4 Earnings ↗

February 11, 2025

Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points.

Via Talk Markets

Topics Stocks Stocks / Equities

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript ↗

February 11, 2025

GILD earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Gilead Sciences Shares Push Higher After Q4 Report: Here's Why ↗

February 11, 2025

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights from the report:

Via Benzinga

Gilead Sciences Beats Q4 EPS Forecast ↗

February 11, 2025

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Via The Motley Fool

Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers

February 11, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects the full...

Via StockStory

Gilead Outplays Veklury Downfall To Obliterate Forecasts. Will Shares Win Back Their Breakout? ↗

February 11, 2025

Gilead obliterated fourth-quarter expectations Tuesday and issued an upbeat profit outlook for 2025.

Via Investor's Business Daily

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.